Gene therapy for pancreatic cancer - Current and prospective strategies

Surgical Oncology

Volumn 9, Issue 4, 2000, Pages 181-191

  Halloran, C M ^a   Ghaneh, P ^a   Neoptolemos, J P ^a   Costello, E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Gene therapy; P16INK4a; p53 and combination chemotherapy; Pancreatic cancer

Indexed keywords

FLUOROURACIL; VIRUS VECTOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DEVELOPING COUNTRY; GENE TARGETING; GENE THERAPY; HUMAN; MEDICAL EXAMINATION; METASTASIS; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SURVIVAL TIME;

EID: 0034434535     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(01)00011-1     Document Type: Article

References (114)

1. Pancreatic cancer resectional outcomes in American university centers 1998-1990
2. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadectomy for periampullary adenocarcinoma: Comparison of morbidity and mortality and short-term exposure
3. Long term survival after curative resection for pancreatic ductal adenocarcinoma: Clinical-pathological analysis of 5-year survivors
4. Lymph node involvement in carcinoma head of pancreas
5. Treatment and survival in 1360 patients with pancreatic cancer, and incidence of the disease in the West Midlands: An epidemiological study
6. Review article: Current treatment and optimal patient management in pancreatic cancer
7. Improvements in survival and clinical benefit with Gemcitabine as first line therapy for patients with advanced pancreatic cancer: A randomised trial
8. Adjuvant treatment for pancreatic cancer
9. Therapy of locally unresectable pancreatic carcinoma: A randomised comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-FU) and high dose radiation+5-FU
10. Adjuvant radiotherapy and follow-on chemotherapy in patients with pancreatic cancer: Results of the UK Pancreatic Cancer Study Group (UKPACA-1)
11. ESPAC-1: An European, randomised controlled study of adjuvant chemoradiation and chemotherapy in respectable pancreatic cancer
12. Adjuvant radiotherapy and 5-FU after curative resection of cancer of the pancreas and periampulliary region
13. Tumour suppressor pathways in pancreatic cancer
14. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma
15. DPC4, a candidate tumour suppressor gene at the human chromosome 18q2.1
16. WAF-1, Cyclin D1, erbb2 and erbb3 in resected pancreatic ductal adenocarcinioma
17. Co-expression of the epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumour aggressiveness
18. Over-expression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumour stage
19. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer
20. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
21. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer
22. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer
23. Signalling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Over expression of caspase-7 as a new gene therapy strategy for prostate cancer
24. Retriviral delivery and tetracycline-dependant expression of IL-beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumour cells
25. Sensitization of colorectal and pancreatic cancer lines to the prodrug 5-aziridin-1-yl-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene
26. Feeding dendritic cells with tumour antigens: Self-service buffet or a la carte?
27. ONYX-015, an E1B gene attenuated adenovirus, causes tumour-specific cytolysis and antitumoural efficacy that can be augmented by standard chemotherapeutic agents
28. Gene therapy: The first decade
29. Cancer gene therapy: Hard lessons and new courses
30. Role of viral antigens in destructive cellular immune response to adenoviral vector transduced cells in mouse lung
31. Gene therapy: Trials and tribulations
32. Retroviral vectors
33. A safe packaging line for gene transfer: Separating viral genes on two different plasmids
34. Safe and efficient generation of retroviruses with amphotropic and ectotropic host ranges
35. Vesicular stomatitis virus G glycoprotein psudotyped retroviral vectors: Concentration to very high titre and efficient gene transfer into mammalian and non-mammalian cells
36. Human gene therapy
37. Self inactivating retroviral vectors designed for transfer of whole genes into mammalian cells
38. The potential for gene therapy in pancreatic cancer
39. Gene therapy for pancreatic and billiary malignancy
40. Lentiviral vectors: Turning a deadly foe into a therapeutic agent
41. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage colony-stimulating factor in human acute lymphoblastic leukaemia and acute myeloid leukaemia cells to induce antileukaemic immune responce
42. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2
43. Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors
44. Transduction of human CD34 cells that mediate long term-term engraftment of NOD/SCID mice by HIV vectors
45. - human haematopoetic cells b HIV-1-based lentiviral vectors
46. Site specific integration of adeno-associated virus
47. Adeno associated viral vectors as gene delivery vehicles
48. Trans splicing vectors expand the utility of adeno-associated virus for gene therapy
49. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complimentary vectors
50. Construction of recombinant adeno-associated virus vector containing the rat preproinsulin II gene
51. Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy
52. An adenovirus mutant that replicates selectively in p53-defecient human tumour cells
53. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication competent adenovirus
54. Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells
55. An Adenovirus-Epstein Barr virus hybrid that stably transforms cultured cells with high efficiency
56. Stable in vivo transduction via a novel adenoviral/retroviral chimeric vector
57. Direct immunologic activities of CpG DNA and implications for gene therapy
58. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases
59. Direct gene transfer into the rat pancreas using DNA-liposomes
60. Transferrin-polycation conjugates as carriers for DNA uptake into cells
61. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells
62. Optimised galenics improve in-vitro gene transfer by cationic molecules up to 1000-fold
63. Direct gene transfer into the rat pancreas using DNA-liposomes
64. A chimeric fusion protein containing transforming growth factor-alpha mediates gene transfer via binding to the EGF receptor
65. Signalling networks that cause cancer
66. Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous ras
67. Target genes and target cells in carcinogenesis
68. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y
69. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice
70. Cytotoxicity CD4+ and CD8+ T lymphocytes generated by mutant p21-ras (12 val) peptide vaccination of a patient recognise 12 val dependant nested epitopes present with in the vaccine peptide and kill autologous tumour cells carrying this mutant
71. Characterisation of immune response in pancreatic cancer patients after mutant p21-ras peptide vaccination
72. Development and characterisation of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumours for use in clinical trials
73. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinoma
74. Ki-ras oncogene activation in pre-invasive pancreatic adenocarcinoma
75. Antisense regulation of oncogenes in human cancer
76. Suppression of p21-ras levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras muations but not those with out Ki-ras mutations
77. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumour dissemination in the murine peritoneal cavity
78. Ribozyme as an approach for growth suppression of human pancreatic cancer
79. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma
80. CaSm: An Sm like protein that contributes to the transformed state in cancer cells
81. The cancer-associated Sm-like oncogene: A novel target for the gene therapy of pancreatic cancer
82. INK4A expression on cell cycle arrest are determined by endogenous p16 and RB status in human cancer cells
83. Abnormalities of the rb1 and dcc tumour suppresser genes-uncommon in human pancreatic adenocarcinoma
84. KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumourigenicity
85. INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation
86. Adenovirus mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro
87. Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16 (INK4A) fusion peptide in pancreatic cancer cells
88. INK4A results in pancreatic cancer regression in vitro and in vivo
89. INK4A and p53 genes cooperate to induce apoptotic tumour cell death
90. Genetic background determines the response to adenovirus-mediated wild-type expression in pancreatic tumour cells
91. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumour
92. Reversible, p16 mediated cell cycle arrest as protection from chemotherapy
93. 1 arrest and protects from praclitaxel and topptecan: Implications for therapy
94. p16INK4A expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerse inhibitors
95. INK4A on chemosensitivity in nasopharygeal carcinoma cells
96. Oncoprotein MDM2 conceals the activation domain of tumour suppresser p53
97. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
98. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
99. Nucleolar Arf sequesters Mdm2 and activates p53
100. Tissue-specific alternate splicing in the human INK4a/ARF cell cycle regulatory locus
101. The ARF/p53 pathway
102. 1 arrest that is suppressed by MDM2
103. Assaignment of the MDM2 binding protein gene (MTBP) to human chromosome band 8q24 by in situ hybridisation
104. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
105. Adenovirus-mediated wild-type p53 tumour suppresser gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
106. Tp53 gene therapy: A key to modulating resistance to anticancer therapies
107. Alteration of drug chemo sensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells
108. Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs
109. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer